Peer-reviewed veterinary case report
Radiation and temozolomide for treating canine malignant melanoma
By Cancedda, S et al.·Published in Veterinary and comparative oncology·2016·Centro Oncologico Veterinario, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma.
- Species:
- dog
Plain-English summary
A study looked at dogs with malignant melanoma, a serious skin cancer, to see how effective radiation therapy alone was compared to radiation therapy followed by a chemotherapy drug called temozolomide. Fifteen dogs received just radiation, while twelve dogs received radiation and then temozolomide. Both groups had similar response rates, but the dogs that received temozolomide had a longer time before the cancer progressed. Both treatments were well tolerated, suggesting that adding temozolomide after radiation could be beneficial for dogs with this type of cancer.
People also search for: dog melanoma treatment · radiation therapy for dogs · temozolomide side effects in dogs
Abstract
Prognosis for unresectable canine malignant melanoma (MM) is typically poor, and therapeutic approaches remain largely palliative. A bi-institutional trial was conducted to compare efficacy and safety of radiation therapy (RT) and RT with post-radiation temozolomide in dogs with chemotherapy-naïve, measurable MM. RT consisted of 5 × 6 Gy fractions over 2.5 weeks. Dogs whose owners wished to pursue chemotherapy received adjuvant oral temozolomide (60 mg mfor 5 days every 28 days). Fifteen dogs were treated with RT only (Group 1) and 12 dogs subsequently received temozolomide (Group 2). Overall response rate was similar between Group 1 (86.7%) and Group 2 (81.1%). Median time to progression (TTP) was significantly longer in Group 2 (205 days) compared to Group 1 (110 days; p = 0.046). Survival time was not significantly different between groups. Both treatments were well tolerated. Post-radiation temozolomide has a good safety profile, and may improve TTP in MM when compared to coarse fractionated RT.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25382434/